Nutritional and nutraceutical considerations for dyslipidemia

Future Lipidology

Volumn 2, Issue 3, 2007, Pages 313-339

  Sirtori, Cesare R ^a   Anderson, James W ^b   Arnoldi, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Cardiovascular disease prevention; Cholesterol; Diet; Functional food; Nutraceutical

Indexed keywords

ALCOHOL; ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; ANTIOXIDANT; CARBOHYDRATE; CHOLESTEROL; COLESTYRAMINE; FAT; FENOFIBRATE; FISH OIL; FISH PROTEIN; GARLIC EXTRACT; GEMFIBROZIL; GUGGULSTERONE; ISPAGULA; LIPOPROTEIN; MONOUNSATURATED FATTY ACID; NUTRACEUTICAL; OLIGOSACCHARIDE; OMEGA 3 FATTY ACID; PEPTIDE; PHYTOSTEROL; PLACEBO; POLYPHENOL; PRAVASTATIN; SIMVASTATIN; SOYBEAN PROTEIN; THROMBOXANE; TRACE ELEMENT; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIET SUPPLEMENTATION; DYSLIPIDEMIA; FAT INTAKE; FEEDING BEHAVIOR; HUMAN; HYPERCHOLESTEROLEMIA; NONHUMAN; NUTRIENT; NUTRITION; OXIDATION; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW; RISK REDUCTION; THROMBOCYTE AGGREGATION;

EID: 34250354745     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.2.3.313     Document Type: Review

References (260)

1. Anderson JW, Konz EO: Obesity and disease management: effects of weight loss on co-morbid conditions. Obes. Res. 9, S326-S334 (2001).
2. Khot UN, Khot MB, Badzer CT et al.: Prevalence of conventional risk factors in patients with coronary heart disease. J. Amer. Med. Assoc. 290, 898-904 (2003).
3. Hasler CF: Functional foods: benefits, concerns and challenges. A position paper from the American Council on Science and Health. J. Nutr. 132, 3772-3781 (2002).
4. Stampfer MJ, Hu FB, Manson JE, Rimm EB, Willett WP: Primary prevention of coronary heart disease in women through diet and lifestyle. N. Engl. J. Med. 343, 16-22 (2000).
5. Kris-Etherton PM, Etherton TD, Carlson J, Gardner R: Recent discoveries in inclusive food-based approaches and dietary patterns for reduction in risk for cardiovascular disease. Curr. Opin. Lipidol. 13, 397-407 (2002).
6. Lichtenstein AH, Appel LJ, Brands M et al.: Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 114, 82-96 (2006).
7. Geil PB, Anderson JW, Gustafson NW: Women and men with hypercholesterolemia respond similarly to an American Heart Association step 1 diet. J. Am. Diet. Assoc. 95, 436-441 (1995).
8. Obarzanek E, Sacks FM, Vollmer WM et al.: Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am. J. Clin. Nutr. 74, 80-89 (2001).
9. Jenkins DJ, Kendall CW, Marchie A et al.: Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am. J. Clin. Nutr. 81, 380-387 (2005).
10. Anderson JW, Ward H: High-carbohydrate, high-fiber diets for insulin-treated men with diabetes mellitus. Am. J. Clin. Nutr. 32, 2312-2321 (1979).
11. Story L, Anderson JW, Chen WJL, Karounos D, Sieling A: Adherence to high-carbohydrate, high-fiber diets: long-term studies of non-obese diabetic men. J. Am. Diet. Assoc. 85, 1105-1110 (1985).
12. Anderson JW, Garrity TF, Wood CL, Whitis SE, Smith BM, Oeltgen PP: Prospective, randomized, controlled comparison of the effects of low-fat and low-fat plus high-fiber diets on serum lipid concentrations. Am. J. Clin. Nutr. 56, 887-894 (1992).
13. Jenkins DJ, Kendall CW, Faulkner D et al.: A dietary portfolio approach to cholesterol reduction: combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 51, 1596-1604 (2002).
14. Jenkins DJ, Kendall CW, Faulkner DA et al.: Assessment of the longer-term effects of a dietary portfolio of cholesterol-lowering foods in hypercholesterolemia. Am. J. Clin. Nutr. 83, 582-591 (2006).
15. Kearney JM, McElhone S: Perceived barriers in trying to eat healthier - results of a pan-EU consumer attitudinal survey. Br. J. Nutr. 81(Suppl. 2), S133-S137 (1999).
16. de Roos NT: The potential and limits of functional foods in preventing cardiovascular disease. In: Functional Foods: Cardiovascular Disease and Diabetes. Arnoldt A (Ed.). Woodhead Publishing Ltd, Cambridge, UK 1-9 (2004).
17. Coppens P, da Silva MF, Pettman S: European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety. Toxicology 221, 59-74 (2006).
18. Jenkins DJ, Kendall CW, Marchie A et al.: Dose response of almonds on coronary heart disease risk factors: blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: a randomized, controlled, crossover trial. Circulation 106, 1327-1332 (2002).
19. Stevinson C, Pittler MH, Ernst E: Garlic for treating hypercholesterolemia. A meta-analysis of randomized clinical trials. Ann. Intern. Med. 133, 420-429 (2000).
20. Lucas EA, Wild RD, Hammond LJ et al.: Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J. Clin. Endocrinol. Metab. 7, 1527-1532 (2002).
21. Wolfs M, de Jong N, Ocke MC, Verhagen H, Monique Verschuren WM: Effectiveness of customary use of phytosterol/-stanol enriched margarines on blood cholesterol lowering. Food Chem. Toxicol. 44, 1682-1688 (2006).
22. Hulshof KF, Brussaard JH, Kruizinga AG, Telman J, Lowik MR: Socio-economic status, dietary intake and 10 year trends: the Dutch National Food Consumption Survey. Eur. J. Clin. Nutr. 57, 128-37 (2003).
23. Thomas D, Frankenberg E: Health, nutrition and prosperity: a microeconomic perspective. Bull. World Health Organ. 80, 106-113 (2002)
24. de Jong N, Ocke MC, Branderhorst HA, Friele R: Demographic and lifestyle characteristics of functional food consumers and dietary supplement users. Br. J. Nutr. 89, 273-281 (2003).
25. Anttolainen M, Luoto R, Uutela A et al.: Characteristics of users and nonusers of plant stanol ester margarine in Finland: an approach to study functional foods. J. Am. Diet. Assoc. 101, 1365-1368 (2001).
26. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. J. Am. Med. Assoc. 251, 351-364 (1984).
27. Manninen V, Elo MO, Frick MH et al.: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. J. Am. Med. Assoc. 260, 641-651 (1988).
28. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
29. Packard CJ, Sheperd J, Cobbe SM et al.: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 97, 1440-1445 (1998).
30. Sacks FM, Pfeffer MA, Lemuel A et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001-1009 (1996).
31. Tonkin AM, Colquhoun D, Emberson J et al.: Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 356, 1871-1875 (2000).
32. Robins SJ, Collins D, Wittes JT et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT, a randomized controlled trial. J. Am. Med. Assoc. 285, 1585-1591 (2001).
33. Shepherd J, Blauw GJ, Murphy MB et al.: On behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 360, 1623-1630 (2002).
34. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo controlled trial. Lancet 360, 7-22 (2002).
35. Colhoun HM, Betteridge DJ, Durrington PN et al.: CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
36. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet 366, 1849-1861 (2005).
37. Knopp RH, d'Emden M, Smilde JG, Pocock SE: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with Type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29, 1478-1485 (2006).
38. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
39. Cannon CP, Braunwald E, McCabe CH et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
40. Holme I, Haaheim LL, Tonstad S, Hjermann I: Effect of dietary and antismoking advice on the incidence of myocardial infarction: a 16-year follow-up of the Oslo Diet and Antismoking Study after its close. Nutr. Metab. Cardiovasc. Dis. 16, 330-338 (2006).
41. Park EJ, Hellerstein MC: Carbohydrate-induced hypertriacylglycerolemia: historical perspective and review of biological mechanisms. Am. J. Clin. Nutr. 71, 412-433 (2000).
42. Anderson JW: Dietary fiber prevents carbohydrate-induced hypertriglyceridemia. Curr. Atheroscler. Rep. 2, 536-541 (2000).
43. Frost G, Leeds AA, Dore CJ, Madeiros S, Brading S, Dornhorst G: Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 353, 1045-1048 (1999).
44. Anderson JW, Randles KM, Kendall CWC, Jenkins DJC: Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J. Am. Coll. Nutr. 23, 5-17 (2004).
45. Kirby RW, Anderson JW, Sieling B et al.: Oat-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men. Am. J. Clin. Nutr. 34, 824-829 (1981).
46. Anderson JW, Zettwoch N, Feldman T, Tietyen-Clark J, Oeltgen P, Bishop CC: Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men. Arch. Intern. Med. 148, 292-296 (1988).
47. Anderson JW, Allgood LD, Lawrence A, Altringer LA, Jerdack GR, Hengehold DC: Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am. J. Clin. Nutr. 71, 472-479 (2000).
48. Ripsin CM, Keenan JM, Jacobs DR et al.: Oat products and lipid lowering. J. Amer. Med. Assoc. 267, 3317-3325 (1992).
49. Brown L, Rosner B, Willett WW, Sacks FM: Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am. J. Clin. Nutr. 69, 30-42 (1999).
50. Önning G: The use of cereal β-glucans to control diabetes and cardiovascular disease. In: Functional Foods, Diet, Cardiovascular Disease and Diabetes. Arnoldi A (Ed.). Woodhead Publishing Ltd, Cambridge, UK 402-421 (2004).
51. Theuwissen E, Mensink RP: Simultaneous intake of β-glucan and plant stanol esters affects lipid metabolism in slightly hypercholesterolemic subjects. J. Nutr. 137, 583-588 (2007).
52. Anderson JD: Dietary fibre, complex carbohydrate and coronary artery disease. Can. J. Cardiol. 11, G55-G62 (1995).
53. Anderson JW, Davidson MH, Blonde L et al.: Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. Am. J. Clin. Nutr. 71, 1433-1438 (2000).
54. Passi SJ, Manchanda SC, Suri S, Bhandari S, Kalra H: Lipid lowering effect of dietary fibre supplementation through food based approach. Asia Pac. J. Clin. Nutr. 13(Suppl.), S155 (2004).
55. Anderson JW, Gilinsky NH, Deakins DA et al.: Hypocholesterolemic effects of different bulk-forming hydrophilic fibers as adjuncts to dietary therapy in mild to moderate hypercholesterolemia. Arch. Intern. Med. 151, 1597-1602 (1991).
56. Yamada K, Tokunaga Y, Ikeda A et al.: Dietary effect of guar gum and its partially hydrolyzed product on the lipid metabolism and immune function of Sprague-Dawley rats. Biosci. Biotechnol. Biochem. 63, 2163-2167 (1999).
57. Davidson MH, Maki KC: Effects of dietary inulin on serum lipids. J. Nutr. 129, S1474-S1477 (1999).
58. Kim DN, Lee KT, Reiner JM, Thomas WA: Increased steroid excretion in swine fed high-fat, high-cholesterol diet with soy protein. Exp. Mol. Pathol. 33, 25-35 (1980).
59. Terpstra AHM, Woodward CJH, West CE, Van Boven JG: A longitudinal cross-over study of serum cholesterol and lipoproteins in rabbits fed on semipurified diets containing either casein or soya-bean protein. Br. J. Nutr. 47, 213-219 (1982).
60. Sirtori CR, Agradi E, Conti F, Mantero O, Gatti E: Soybean-protein diet in the treatment of Type II hyperlipoproteinaemia. Lancet 1, 275-277 (1977).
61. Descovich GC, Ceredi C, Gaddi A et al.: Multicentre study of soybean protein diet for outpatient hypercholesterolaemic patients. Lancet 2, 709-712 (1980).
62. Gaddi A, Descovich GC, Noseda G et al.: Hypercholesterolaemia treated by soybean protein diet. Arch. Dis. Child. 62, 274-278 (1987).
63. Sirtori CR, Lovati MR, Manzoni C et al.: Reduction of serum cholesterol by soybean proteins: clinical experience and potential molecular mechanisms. Nutr. Metab. Cardiovasc. Dis. 8, 334-340 (1998).
64. Bakhit RM, Klein BP, Essex Sorlie D et al.: Intake of 25 g of soybean protein with or without soybean fiber alters plasma lipids in men with elevated cholesterol concentrations. J. Nutr. 124, 213-222 (1994).
65. FDA Food labeling health claims: soybean protein and coronary heart disease. Food and Drug Administration. Final rule. Federal Register 64, 57699-57733 (1999).
66. Zhang X, Shu XO, Gao Y-T et al.: Soy food consumption is associated with lower risk of coronary heart disease risk reduction in Chinese women. J. Nutr. 133, 2874-2878 (2003).
67. Nagata C, Takatsuka N, Kurisu Y, Shimizu H: Decreased serum total cholesterol concentration is associated with high intake of soy products in Japanese men and women. J. Nutr. 128, 209-213 (1998)
68. Burslem J, Schonfeld G. Howald MA, Weidman S, Miller JP: Plasma apoprotein and lipoprotein lipid levels in vegetarians. Metabolism 27, 711-719 (1978).
69. Rosell MS, Appleby PN, Spencer EA, Key TJ: Soy intake and blood cholesterol concentrations: a cross-sectional study of 1033 pre- and postmenopausal women in the Oxford arm of the European Prospective Investigation into Cancer and Nutrition. Am. J. Clin. Nutr. 80, 1391-1396 (2004).
70. Halton TL, Willett WC, Liu S et al.: Low-carbohydrate-diet score and the risk of coronary heart disease in women. N. Engl. J. Med. 355, 1991-2002 (2006).
71. Carroll KK: Hypercholesterolemia and atherosclerosis: effects of dietary protein. Fed. Proc. 41, 2792-2796 (1982).
72. Huff MW, Hamilton RM, Carroll KK: Plasma cholesterol levels in rabbits fed low fat, cholesterol-free, semipurified diets: effects of dietary proteins, protein hydrolysates and amino acid mixtures. Atherosclerosis 28, 187-195 (1977).
73. Anderson JW, Johnstone BM, Cook Newell ME: Meta-analysis of the effects of soy protein intake on serum lipids. N. Engl. J. Med. 333, 276-282 (1995).
74. Anderson JS: Soy food effects on serum lipoproteins in humans: updated meta-analysis. Role of Soy in Preventing and Treating Chronic Diseases. Proceedings of the Sixth International Symposium. Chicago, IL, USA, 11-12 June 2005 (Abstract).
75. Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M: American Heart Association Nutrition Committee: Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation 113, 1034-1044 (2006).
76. Sirtori CR, Eberini I, Arnoldi A: Hypocholesterolaemic effects of soya proteins: results of recent studies are predictable from the Anderson's meta-analysis data. Br. J. Nutr. 97, 816-822 (2007).
77. Anthony MS, Clarkson TB, Hughes CL Jr, Morgan TM, Burke GS: Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J. Nutr. 126, 43-50 (1996).
78. Greaves KA, Parks JS, Williams JK, Wagner JI: Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J. Nutr. 129, 1585-1592 (1999).
79. Sirtori CR, Arnoldi A, Johnson SK: Phytoestrogens: end of a tale. Ann. Med. 37, 423-438 (2005).
80. Sirtori CR, Galli G, Lovati MR, Carrara P, Bosisio E, Kienle MG: Effects of dietary proteins on the regulation of liver lipoprotein receptors in rats. J. Nutr. 114, 1493-1500 (1984).
81. Lovati MR, Manzoni C, Gianazza E et al.: Soy protein peptides regulate cholesterol homeostasis in Hep G2 cells. J. Nutr. 130, 2543-2549 (2000).
82. Anderson JW, Story L, Sieling B, Chen WJ, Petro MS, Story J: Hypocholesterolemic effects of oat-bran or bean intake for hypercholesterolemic men. Am. J. Clin. Nutr. 40, 1146-1155 (1984).
83. Fumagalli R, Soleri L, Farina R et al.: Fecal cholesterol excretion studies in type II hypercholesterolemic patients treated with the soybean protein diet. Atherosclerosis 43, 341-353 (1982).
84. Lovati MR, Manzoni C, Canavesi A et al.: Soybean protein diet increases low density lipoprotein receptor activity in mononuclear cells from hypercholesterolemic patients. J. Clin. Invest. 80, 1498-1502 (1987).
85. Baum JA, Teng H, Erdman JW et al.: Long-term intake of soy protein improves blood lipid profiles and increases mononuclear cell low-density-lipoprotein receptor messenger RNA in hypercholesterolemic, postmenopausal women. Am. J. Clin. Nutr. 68, 545-551 (1998).
86. Gianazza G, Eberini I, Arnoldi A, Wait R, Sirtori CR: A proteomic investigation of isolated soy proteins with variable effects in experimental and clinical studies. J. Nutr. 133, 9-14 (2003).
87. Lovati MR, Manzoni C, Corsini A, Granata A, Fumagalli R, Sirtori CR: 7S globulin from soybean is metabolized in human cell cultures by a specific uptake and degradation system. J. Nutr. 126, 2831-2842 (1996).
88. Lovati MR, Manzoni C, Corsini A et al.: Low density lipoprotein receptor activity is modulated by soybean globulins in cell culture. J. Nutr. 122, 1971-1978 (1992).
89. Duranti M, Lovati, MR, Dani V et al.: The α-subunit from soybean 7S globulin lowers plasma lipids and upregulates liver β-VLDL receptors in rats fed a hypercholesterolemic diet. J. Nutr. 134, 1334-1339 (2004).
90. Adams MR, Golden DL, Franke AA, Potter SM, Smith HS, Anthony MS: Dietary soy β-conglycinin (7S globulin) inhibits atherosclerosis in mice. J. Nutr. 134, 511-516 (2004).
91. Ni W, Tsuda Y, Takashima S, Sato H, Sato M, Imaizumi K: Anti-atherogenic effect of soya and rice-protein isolate, compared with casein, in apolipoprotein E-deficient mice. Br. J. Nutr. 90, 13-20 (2003).
92. Wang M-F, Yamamoto S, Chung H-M et al.: Antihypercholesterolemic effect of undigested fraction of soybean protein in young female volunteers. J. Nutr. Sci. Vitaminol. 41, 187-195 (1995).
93. Hori G, Wang M-F, Chan Y-C et al.: Soy protein hydrolyzate with bound phospholipids reduces serum cholesterol levels in hypercholesterolemic adult male volunteers. Biosci. Biotechnol. Biochem. 65, 72-78 (2001).
94. Arnoldi A: Grain legumes as a source of food ingredients for the prevention of cardiovascular disease. In: Functional Foods, Diet, Cardiovascular Disease and Diabetes. Arnoldi A (Ed.). Woodhead Publishing Ltd, Cambridge, UK 422-447 (2004).
95. Rahman MH, Hossain A, Siddiqua A, Hossain I: Hemato-biochemical parameters in rats fed Lupinus angustifolius L. (sweet lupin) seed protein and fiber fraction. J. Clin. Biochem. Nutr. 20, 99-111 (1996).
96. Sirtori CR, Duranti M, Magni C et al.: The proteins of lupin - a naturally isoflavones-free legume - reduce cholesterolemia and increase LDL receptor activity in animal and cell models. J. Nutr. 134, 18-23 (2004).
97. Staels B, van Tol A, Andreu T, Auwerx J: Fibrates influence the expression of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler. Thromb. 12, 286-294 (1992).
98. Wait R, Gianazza R, Brambilla D et al.: Analysis of Lupinus albus storage proteins by two dimensional electrophoresis and mass spectrometry. J. Agric. Food Chem. 53, 4599-606 (2005).
99. Locati D, Morandi S, Zanotti M, Arnoldi A: A fast and simple method for the detection of the major storage proteins of lupin food ingredients using HPLC-ESI-MS/MS. Rapid Commun. Mass Spectrom. 20, 1305-1316 (2006).
100. Pilvi TK, Jauhiainen T, Cheng ZJ, Mervaala EM, Vapaatalo H, Korpela R: Lupin protein attenuates the development of hypertension and normalises the vascular function of NaCl-loaded Goto-Kakizaki rats. J. Physiol. Pharmacol. 57, 167-176 (2006).
101. Lasekan JB, Gueth L, Khan S: Influence of dietary golden pea proteins versus casein on plasma and hepatic lipids in rats. Nutr. Res. 15, 71-84 (1995).
102. Alonso R, Grant G, Marzo F: Thermal treatment improves nutritional quality of pea seeds (Pisum sativum L.) without reducing their hypocholesterolemic properties. Nutr. Res. 21, 1067-1077 (2001).
103. Zulet MA, Macarulla MT, Portillo MP, Noel-Suberville C, Higueret P, Martinez JA: Lipid and glucose utilization in hypercholesterolemic rats fed a diet containing heated chickpea (Cicer aretinum L.): a potential functional food. Int. J. Vitam. Nutr. Res. 69, 403-411 (1999).
104. Macarulla MT, Medina C, De Diego MA et al.: Effects of the whole seed and a protein isolate of faba bean (Vicia faba) on the cholesterol metabolism of hypercholesterolaemic rats. Br. J. Nutr. 85, 607-614 (2001).
105. Dabai FD, Walker AF, Sambrook IE, Welch VA, Owen RW, Abeyasekera S: Comparative effects on blood lipids and fecal steroids of five legume species incorporated into a semi-purified, hypercholesterolemic rat diet. Br. J. Nutr. 75, 557-571 (1996).
106. Kingman SM, Walker AF, Low AG, Sambrook IE, Owen RW, Cole TJ: Comparative effects of four legume species on plasma lipids and fecal steroid excretion in hypercholesterolaemic pigs. Br. J. Nutr. 69, 409-421 (1993).
107. Martins JM, Riottot M, de Abreu MC et al.: Cholesterol-lowering effects of dietary blue lupin (Lupinus angustifolius L.) in intact and ileorectal anastomosed pigs. J. Lipid Res. 46, 1539-1547 (2005).
108. Martins JM, Riottot M, de Abreu MC et al.: Dietary raw peas ( Pisum sativum L.) reduce plasma total and LDL cholesterol and hepatic esterified cholesterol in intact and ileorectal anastomosed pigs fed cholesterol-rich diets. J. Nutr. 134, 3305-3312 (2004).
109. Anderson JW, Gustafson NJ, Spencer DB, Tietyen J, Bryant CA: Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans. Am. J. Clin. Nutr. 51, 1013-1019 (1990).
110. Cobiac L, McArthur R, Nestel PJ: Can eating baked beans lower plasma cholesterol? Eur. J. Clin. Nutr. 44, 819-822 (1990).
111. Oosthuizen W, Scholtz CS, Vorster HH, Jerling JC, Vermaak WJ: Extruded dry beans and serum lipoprotein and plasma haemostatic factors in hyperlipidaemic men. Eur. J. Clin. Nutr. 54, 373-379 (2000).
112. Jenkins DJ, Wong GS, Patten R et al.: Leguminous seeds in the dietary management of hyperlipidemia. Am. J. Clin. Nutr. 38, 567-573 (1983).
113. Mackay S, Ball MJ: Do beans and oat bran add to the effectiveness of a low-fat diet? Eur. J. Clin. Nutr. 46, 641-648 (1992).
114. Fruhbeck G, Monreal I, Santidrian S: Hormonal implications of the hypocholesterolemic effect of intake of field beans (Vicia faba L.) by young men with hypercholesterolemia. Am. J. Clin. Nutr. 66, 1452-1460 (1997).
115. Anderson JW, Major AW: Pulses and lipaemia, short and long-term effect: potential in the prevention of cardiovascular disease. Br. J. Nutr. 88(Suppl. 3). S263-S271 (2002).
116. Zhang X, Beynen AC: Influence of dietary fish proteins on plasma and liver cholesterol concentrations in rats. Br. J. Nutr. 69, 767-777 (1993).
117. Sirtori CR, Crepaldi G, Manzato E et al.: One-year treatment with ethyl-esters of n-3 fatty acids in patients with hypertriglyceridemia and glucose intolerance. Reduced triglyceridemia, total cholesterol and increased HDL-C without glycemic alterations. Atherosclerosis 137, 419-427 (1998).
118. Shukla A, Bettzieche A, Hirche F, Brandsch C, Stangl GI, Eder K: Dietary fish protein alters blood lipid concentrations and hepatic genes involved in cholesterol homeostasis in the rat model. Br. J. Nutr. 96, 674-682 (2006).
119. Mensink RP, Zock PL, Kester AD, Katan MB: Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr. 77, 1146-1155 (2003).
120. Gill JMR, Brown JC, Caslake MJ et al.: Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. Am. J. Clin. Nutr. 78, 47-56 (2003).
121. Gerhard GT, Ahmann A, Meeuws K, McMurry MP, Duell PB, Connor WE: Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins, and glycemic control in Type 2 diabetes. Am. J. Clin. Nutr. 80, 668-667 (2004).
122. Appel LJ, Sacks FM, Carey VJ et al.: OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. J. Am. Med. Assoc. 294, 2455-2464 (2005).
123. FDA. Letter Responding to Health Claim Petition dated August 28, 2003. Monounsaturated Fatty Acids from Olive Oil and Coronary Heart Disease. (Docket No 2003Q-0559) 11/01/2004.
124. Massaro M, De Caterina R: Vasculoprotective effects of oleic acid: epidemiological background and direct vascular antiatherogenic properties. Nutr. Metab. Cardiovasc. Dis. 12, 42-51 (2002).
125. Sirtori CR, Gatti E, Tremoli E et al.: Olive oil, corn oil, and n-3 fatty acids differently affect lipids, lipoproteins, platelets, and superoxide formation in type II hypercholesterolemia. Am. J. Clin.-Nutr. 56, 113-122 (1992).
126. Sirtori CR, Tremoli E, Gatti E et al.: Controlled evaluation of fat intake in the Mediterranean diet: comparative activities of olive oil and corn oil on plasma lipids and platelets in high-risk patients. Am. J. Clin. Nutr. 44, 635-642 (1986).
127. Whelton SP, He J, Whelton PK, Muntner P: Meta-analysis of observational studies on fish intake and coronary heart disease. Am. J. Cardiol. 93, 1119-1123 (2004).
128. Bucher HC, Hengstler P, Schindler C, Meier G: n-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 112, 298-304 (2002).
129. Konig A, Bouzan C, Cohen T et al.: A quantitative analysis of fish consumption and coronary heart disease mortality. Am. J. Prev. Med. 29, 335-346 (2005).
130. Bouzan C, Cohen JT, Connor WE et al.: A quantitative analysis of fish consumption and stroke risk. Am. J. Prev. Med. 29, 347-352 (2005).
131. Hooper L, Thompson RL, Harrison RA et al.: Omega-3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst. Rev. CD003177 (2004).
132. Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am. J. Clin. Nutr. 65, S1645-S1654 (1997).
133. Maki KC, Van Elswyk ME, McCarthy D et al.: Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. J. Am. Coll. Nutr. 24, 189-199 (2000).
134. Theobald HE, Chowienczyk PJ, Whittall R, Humphries SE, Sanders TAB: LDL cholesterol-raising effect of low-dose docosahexanoic acid in middle-aged men and women. Am. J. Clin. Nutr. 79, 558-563 (2004).
135. Dubey P, Cheema SK: Molecular mechanism involved in the regulation of lipid and lipoprotein metabolism by fish oil. Future Lipidol. 1, 559-568 (2006).
136. Mooradian AD, Haas MJ, Wong NCW: The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr. Rev. 27, 2-16 (2006).
137. Borghi C, Cicero A: Recent evidence of the role of omega-3 polyunsaturated fatty acids on blood pressure control and hypertension-related complications. Future Lipidol. 1, 569-577 (2006).
138. Sirtori CR, Paoletti R, Mancini M et al.: n-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidemia and abnormal glucose tolerance. Italian Fish Oil Multicenter Study. Am. J. Clin. Nutr. 65, 1874-1881 (1997).
139. Calabresi L, Villa B, Canavesi M et al.: An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53, 153-158 (2004).
140. Di Castelnuovo A, Rotondo S, Iacoviello L, Donati MB, De Gaetano G: Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105, 2836-2844 (2002).
141. Gall N: Is wine good for your heart? A critical review. Postgrad. Med. J. 77, 172-176 (2001).
142. Flesch M, Rosenkranz S, Erdmann E, Bohm M: Alcohol and the risk of myocardial infarction. Basic Res. Cardiol. 96, 128-135 (2001).
143. Li JM, Mukamal KJ: An update on alcohol and atherosclerosis. Curr. Opin. Lipidol. 15, 673-680 (2004).
144. Mukamal KJ, Conigrave KM, Mittleman MA et al.: Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N. Engl. J. Med. 348, 109-118 (2003).
145. Taskinen MR, Nikkila EA, Valimaki M et al.: Alcohol-induced changes in serum lipoproteins and in their metabolism. Am. Heart J. 113, 458-464 (1987).
146. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ: Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. Br. Med. J. 319, 1523-1528 (1999).
147. Law M, Wald N: Why heart disease mortality is low in France: the time lag explanation. Br. Med. J. 318, 1471-1476 (1999).
148. Zern TL, Fernandez ML: Cardioprotective effects of dietary polyphenols. J. Nutr. 135, 2291-2294 (2005).
149. Davis HR Jr, Zhu LJ, Hoos LM et al.: Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem. 279, 33586-33592 (2004).
150. Field FJ, Born E, Mathur SN: Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression. J. Lipid Res. 45, 2252-2259 (2004).
151. Davidson MH, Maki KC, Umporowicz DM et al.: Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J. Am. Coll. Nutr. 20, 307-319 (2001).
152. Ntanios FY, Duchateau GS: A healthy diet rich in carotenoids is effective in maintaining normal blood carotenoid levels during the daily use of plant sterol-enriched spreads. Int. J. Vitam. Nutr. Res. 72, 32-39 (2002).
153. Maki KC, Davidson MH, Umporowicz DM et al.: Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am. J. Clin. Nutr. 74, 33-43 (2001).
154. Matvienko OA, Lewis DS, Swanson M et al.: A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am. J. Clin. Nutr. 76, 57-64 (2002).
155. Neil HA, Meijer GW, Roe L: Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 156, 329-337 (2001).
156. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N. Engl. J. Med. 333, 1308-1312 (1995).
157. Hallikainen MA, Uusitupa MI: Effects of two low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Am. J. Clin. Nutr. 69, 403-410 (1999).
158. Gylling H, Radhakrishnan R, Miettinen TA: Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 96, 4226-4231 (1997).
159. Law M: Plant sterol and stanol margarines and health. Br. Med. J. 320, 861-864 (2000).
160. Cater NB, Garcia-Garcia AB, Vega GL, Grundy SM: Responsiveness of plasma lipids and lipoproteins to plant stanol esters. Am. J. Cardiol. 96, 23D-28D (2005).
161. Plat J, Mensink RP: Effects of diets enriched with two different plant stanol ester mixtures on plasma ubiquinol-10 and fat-soluble antioxidant concentrations. Metabolism 50, 520-529 (2001).
162. Vanstone CA, Raeini-Sarjaz M. Parsons WE, Jones PJ: Unesterifted plant sterols and stanols lower LDL-cholesterol concentrations equivalently in hypercholesterolemic persons. Am. J. Clin. Nutr. 76, 1272-1278 (2002).
163. Richelle M, Enslen M, Hager C et al.: Both free and esterified plant sterols reduce cholesterol absorption and the bioavailability of β-carotene and α-tocopherol in normocholesterolemic humans. Am. J. Clin. Nutr. 80, 171-177 (2004).
164. Salo P, Wester I: Low-fat formulations of plant stanols and sterols. Am. J. Cardiol. 96, 51D-54D (2005).
165. Spilburg CA, Goldberg AC, McGill JB et al.: Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J. Am. Diet. Assoc. 103, 577-581 (2003).
166. Clifton P: Plant sterol and stanols - comparison and contrasts. Sterols versus stanols in cholesterol-lowering: is there a difference? Atherosclerosis 3, 5-9 (2002).
167. Hallikainen MA, Sarkkinen ES, Uusitupa MI: Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner. J. Nutr. 130, 767-776 (2000).
168. O'Neill FH, Brynes A, Mandeno R et al.: Comparison of the effects of dietary plant sterol and stanol esters on lipid metabolism. Nutr. Metab. Cardiovasc. Dis. 14, 133-142 (2004).
169. Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R: Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin. Proc. 78, 965-978 (2003).
170. de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJ, Stroes ES: Plant sterols lower LDL cholesterol without improving endothetial function in prepubertal children with familial hypercholesterolaemia. J. Inherit. Metab. Dis. 26, 343-351 (2003).
171. Expert Panel. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Amer. Med. Assoc. 285, 2486-2497 (2001).
172. Craig-Schmidt MC: World-wide consumption of trans fatty acids. Atherosclerosis 7, 1-4 (2006).
173. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E: Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N. Engl. J. Med. 333, 1308-1312 (1995).
174. Griel AE, Kris-Etherton PM: Tree nuts and the lipid profile: a review of clinical studies. Br. J. Nutr. 96(Suppl. 2), S68-S78 (2006).
175. Cortes B, Nunez I, Cofan M et al.: Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. J. Am. Coll. Cardiol. 48, 1666-1671 (2006).
176. Simopoulos AP, Visioli F (Eds): Mediterranean diets. World Review on Nutrition and Dietetics (Volume 87). S Karger AG, Basel, Switzerland (2000).
177. Ducimetière P: La fréquence de la maladie coronaire en France et le "paradoxe français". Médecine /Sciences 16, 1040-1044 (2000).
178. Astrup A, Marckmann P, Blundell J: Oiling of health messages in marketing of food. Lancet 356, 1786 (2000).
179. Merkel M, Velez-Carrasco W, Hiddings LC, Breslow JL: Compared with saturated fatty acids, dietary monunsturated fatty acids and carbohydrates increase atherosclerosis and VLDL cholesterol levels in LDL receptor-deficient, but not apolipoprotein E-deficient, mice. Proc. Natl Acad. Sci. USA 98, 13294-13299 (2001).
180. Marzetta CA, Rudel LL: A species comparison of low density lipoprotein heterogeneity in non human primates fed atherogenic diets. J. Lipid Res. 27, 753-761 (1986).
181. Goldberg IJ, Mosca L, Piano MR, Fisher EA: Wine and your heart. Circulation 103, 472-475 (2001).
182. Gutfinger T: Phenols in olive oil. J. Am. Oil Chem. Soc. 689, 66-68 (1981).
183. Visioli F, Vinceri FF, Galli C: "Waste waters" from olive oil production are rich in natural antioxidants. Experientia 51, 32-34 (1995).
184. Amiot MJ, Fleuriet A, Macheix JJ: Importance and evolution of phenolic compounds in olive during growth and maturation. J. Agric. Food Chem. 34, 823-826 (1986).
185. Tsimidou M, Papadopoulos G, Boskou D: Phenolic compounds and stability of virgin olive oil - Part 1. Food Chem. 45, 141-144 (1992).
186. Visioli F, Bellosta S, Galli C: Oleuropein, the bitter principle of olives, enhances nitric oxide production by mouse macrophages. Life Sci. 62, 541-546 (1998).
187. Visioli F, Bellomo G, Galli C: Free radical-scavenging properties of olive oil polyphenols. Biochem. Biophys. Res. Commun. 247, 60-64 (1998).
188. Visioli F, Bellomo G, Montedoro G, Galli C: Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis 117, 25-32 (1995).
189. Visioli F, Caruso D, Grande S et al.: Virgin Olive Oil Study (VOLOS): vasoprotective potential of extra virgin olive oil in mildly dyslipidemic patients. Eur. J. Nutr. 44, 121-127 (2005).
190. Kohyama N, Nagata T, Fujimoto S, Sekiya K: Inhibition of arachidonate lipoxygenase activities by 2-(3,4-dihydroxyphenyl)ethanol, a phenolic compound from olives. Biosci. Biotech. Biochem. 61, 347-350 (1997).
191. Quiles JL, Ochoa JJ, Ramirez-Tortosa C et al.: Dietary fat type (virgin olive versus sunflower oils) affects age-related changes in DNA double-strand-breaks, antioxidant capacity and blood lipids in rats. Exp. Gerontol. 39, 1189-1198 (2004).
192. Petroni A, Blasevich M, Salami M, Papini N, Montedoro GF, Galli C: Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. Thromb. Res. 78, 151-160 (1995).
193. Gonzalez-Santiago M, Martin-Bautista E, Carrero JJ et al.: One-month administration of hydroxytyrosol, a phenolic antioxidant present in olive oil, to hyperlipemic rabbits improves blood lipid profile, antioxidant status and reduces atherosclerosis development. Atherosclerosis 188, 35-42 (2006).
194. Covas MI, Nyyssonen K, Poulsen HE et al.: The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann. Intern. Med. 145, 333-341 (2006).
195. Hertog MGL, Feskens EJM, Hollman PCH, Katan MB, Kromhout D: Dietary antioxidant flavonoids and risk of coronary heart disease. The Zutphen elderly study. Lancet 342, 1007-1101 (1993).
196. Pignatelli P, Ghiselli A, Buchetti B et al.: Polyphenols synergistically inhibit oxidative stress in subjects given red and white wine. Atherosclerosis 188, 77-83 (2006).
197. Goldberg DM, Yan J, Ng E et al.: A global survey of trans-resveratrol concentrations in commercial wines. Am. J. Enol. Vitic. 46, 159-165 (1995).
198. Pervaiz S: Resveratrol: from grapevines to mammalian biology. FASEB J. 17, 1975-1985 (2003).
199. Frankel EN, Waterhouse AL, Kinsella JE: Inhibition of human LDL oxidation by resveratrol. Lancet 341(8852), 1103-1104 (1993).
200. Holmes-McNary M, Baldwin AS Jr: Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IκB kinase. Cancer. Res. 60, 3477-3483 (2000).
201. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM: Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun. 254, 739-743 (1999).
202. Dorrie J, Gerauer H, Wachter Y, Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer. Res. 61, 4731-4739 (2001).
203. Stef G, Csiszar A, Lerea K, Ungvari Z, Veress G: Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance. J. Cardiovasc. Pharmacol. 48, 1-5 (2006).
204. Ou HC, Chou FP, Sheen HM, Lin TM, Yang CH, Huey-Herng SW: Resveratrol, a polyphenalic compound in red wine, protects against oxidized LDL-induced cytotoxicity in endothelial cells. Clin. Chim. Acta 364, 196-204 (2006).
205. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5, 493-506 (2006).
206. Baur JA, Pearson KJ, Price NL et al.: Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342 (2006).
207. Sumpio BE, Cordova AC, Berke-Schlessel DW, Qin F, Chen QH: Green tea, the "Asian paradox" and cardiovascular disease. J. Am. Coll. Surg. 202, 813-825 (2006).
208. Cooper R, Morre DJ. Morre DM: Medicinal benefits of green tea: Part I. Review of noncancer health benefits. J. Altern. Complement. Med. 11, 521-528 (2005).
209. Peter U, Poole C, Arab I: Does tea affect cardiovascular disease? A meta-analysis. Am. J. Epidemiol. 154, 495-503 (2001).
210. Kuriyama S, Shimazu T, Ohmori K et al.: Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. J. Am. Med. Assoc. 296, 1255-1265 (2006).
211. Davies MJ, Judd JT, Baer DJ et al.: Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults. J. Nutr. 133, S3298-S3302 (2003).
212. Yang CS, Landau JM: Effects of tea consumption on nutrition and health. J. Nutr. 130, 2409-2412 (2000).
213. McKay DL, Blumberg JB: The role of tea in human health: an update. J. Am. Coll. Nutr. 21, 1-13 (2002).
214. Cornelis MC, El-Sohemy A: Coffee, caffeine, and coronary heart disease. Curr. Opin. Lipidol. 18, 13-19 (2007).
215. Knekt P, Ritz J, Pereira MA et al.: Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts. Am. J. Clin. Nutr. 80, 1508-1520 (2004).
216. Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A: Antioxidant vitamins and lipid theory: end of a long romance? Arterioscler. Thromb. Vasc. Biol. 22(10), 1535-1546 (2002).
217. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015-2022 (2002).
218. Wald DS, Law M, Morris JK: Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. Br. Med. J. 325, 1202 (2002).
219. Wald NJ, Law MR, Morris JK, Wald DS: Quantifying the effect of folic acid. Lancet 358, 2069-2073 (2001).
220. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 354, 1567-1577 (2006).
221. Bonaa KH, Njoistad I, Ueland PM et al.: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N. Engl. J. Med. 354, 1578-1588 (2006).
222. Loscalzo J: Homocysteine trials - clear outcomes for complex reasons. N. Engl. J. Med. 354, 1629-32 (2006).
223. Craig WJ: Health-promoting properties of common herbs. Am. J. Clin. Nutr. 70, S491-S499 (1999).
224. Tapsen LC, Hemphill I, Cobiac L et al.: Health benefits of herbs and spices: the past, the present, the future. Med. J. Aust. 185, S4-S24 (2006).
225. Ackermann RT, Mulrow CD, Ramirez G, Gardner CD, Morbidoni L, Lawrence VA: Garlic shows promise for improving some cardiovascular risk factors. Arch. Intern. Med. 161, 813-824 (2001).
226. van Doorn MB, Espirito Santo SM, Meijer P, Kamerling IM, Schoemaker RC, Dirsch V: Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects. Am. J. Clin. Nutr. 84, 1324-1329 (2006).
227. Amagase H: Clarifying the real bioactive constituents of garlic. J. Nutr. 136, S716-S725 (2006).
228. Gardner CD, Lawson LD, Block E et al.: Effect of raw garlic versus commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch. Intern. Med. 167, 346-353 (2007).
229. Heber D, Yip I, Ashley IM. Elashoff DA, Elashoff RM. Go VL: Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am. J. Clin. Nutr. 69, 231-236 (1999).
230. Zhao SP, Liu L, Cheng YC et al.: Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart diseae. Circulation 110, 915-920 (2004).
231. Coon JST, Ernst E: Herbs for serum cholesterol reduction. J. Fam. Pract. 52, 468-478 (2003).
232. Keithiey JK, Swanson B, Sha BE, Zeller JM, Kessler HA, Smith KY. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition 18, 201-204 (2002).
233. Szapary PO, Wolfe ML, Bloedon LT et al.: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290, 765-772 (2003).
234. Singh RB, Niaz MA, Ghosh S: Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc. Drugs Ther. 8, 659-664 (1994).
235. Kuppurajan K, Rajagopalan SS, Rao TK, Sitaraman R: Effect of guggulu ( Commiphora mukul Engl.) on serum lipids in obese, hypercholesterolemic and hyperlipemic cases. J. Assoc. Physicians India 26, 367-373 (1978).
236. Singh RB, Niaz MA, Rastogi V, Postiglione A, Rastogi SS: Hypolipidemic and antioxidant effects of fenugreek seeds and triphala as adjuncts to dietary therapy in patients with mild to moderate hypercholesterolemia. Perfusion 11, 124-130 (1998).
237. Gouni-Berthold I, Berthold HK: Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am. Heart J. 143, 356-365 (2002).
238. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I: Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295, 2262-2269 (2006).
239. Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G: A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am. J. Clin. Nutr. 69, 213-219 (1999).
240. Mustad VA, Smith CA, Ruey PP, Edens NK, DeMichele, SJ: Supplementation with 3 compositionally different tocotrienol supplements does not improve cardiovascular disease risk factors in men and women with hypercholesterolemia. Am. J. Clin. Nutr. 76, 1237-1243 (2002).
241. Englisch W, Beckers C, Unkauf M, Ruepp M, Zinserling V: Efficacy of Artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung 50, 260-265 (2000).
242. Pittler MH. Thompson CO, Ernst E: Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst. Rev. CD003335 (2002).
243. Wan Y, Vinson JA, Etherton TD, Proch J, Lazarus SA, Kris-Etherton PM: Effects of cocoa powder and dark chocolate on LDL oxidative susceptibility and prostaglandin concentrations in humans. Am. J. Clin. Nutr. 74, 596-602 (2001).
244. Engler MB, Engler MM, Chen CY et al.: Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J. Am. Coll. Nutr. 23, 197-204 (2004).
245. Ding EL, Hutfless SM, Ding X. Girotra S: Chocolate and prevention of cardiovascular disease: a systematic review. Nutr. Metab. (Lond.) 3, 2 (2006).
246. Anderson RA, Broadhurst CL, Polansky MM et al.: Isolation and characterization of polyphenol type-A polymers fromcinnamon with insulin-like biological activity. J. Agric. Food Chem. 52. 65-70 (2004).
247. Khan A. Safdar M, Ii Khan MM, Khattak KN, Anderson RA: Cinnamon improves glucose and lipids of people with Type 2 diabetes. Diabetes Care 26, 3215-3218 (2003).
248. Cheung MC, Zhao X-Q, Chait A, Albers JJ, Brown G: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler. Thromb. Vase. Biol. 21, 1320-1326 (2001).
249. Mooradian AD, Haas MJ, Wadud K: Ascorbic acid and α-tocopherol down-regulate apotipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 55, 159-167 (2006).
250. Mooradian AD, Haas MJ, Wong NCW: The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Endocr. Rev. 27, 2-16 (2006).
251. Wehmeier K, Beers A, Haas MJ, Wong NC et al.: Inhibition of apolipoprotein AI gene expression by 1,25-dihydroxyvitamin D3. Biochim. Biophys. Acta 1737, 16-26 (2005).
252. Berthou L, Langouet S. Grude P. Denefle P. Branellec D, Guillouzo A: Negative regulation of ApoA-I gene expression by retinoic acid in rat hepatocytes maintained in a co-culture system. Biochim. Biophys. Acta 1391, 329-336 (1998).
253. Haas MJ, Sawaf R. Horani MH, Gobal F, Wong NCW, Mooradian AD: Effect of chromium on apolipoprotein A-I expression in HepG2 cells. Nutrition 19, 353-357 (2003).
254. Ernst E: The risk-benefit profile of commonly used herbal therapies: Ginkgo, St John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann. Intern. Med. 136, 42-53 (2002).
255. Goldman P: Herbal medicines today and the roots of modern pharmacology. Ann. Intern. Med. 135, 594-600 (2001).
256. De Smet PA: Herbal remedies. N. Engl. J. Med. 347, 2046-2056 (2002).
257. Ordovas JM, Corella D: Nutritional genomics. Annu. Rev. Genomics Hum. Genet. 5, 71-118 (2004).
258. Tai ES, Corella D, Deurenberg-Yap M et al.: Singapore National Health Survey. Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. J. Nutr. 133, 3399-3408 (2003).
259. Tai ES, Corena D, Demissie S et al.: Framingham heart study. Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J. Nutr. 135, 397-403 (2005).
260. Marcus DM: A commentary on the American Society for Clinical Pharmacology and Therapeutics position statement on dietary supplement safety and regulationn Clin. Pharmacol. Ther. 78, 114-117 (2005).